News & Trade Shows

News & Trade shows


Biomerica Highlights Recent Scientific Reports
10/4/2016
 

Irvine, Calif. -- October 4, 2016 -- Biomerica, Inc. (NASDAQ: BMRA), a global provider of advanced diagnostic products, today emphasized the market opportunity created by global market failure to effectively treat irritable bowel syndrome (IBS), further establishing the Company's unique approach to identifying patient specific foods that, when removed from an individual's diet, can alleviate IBS symptoms.

According to a recent study and poster published by Fabiane B. Klem, M.D., of the Universidade Federal do Parana, approximately one in nine people develop irritable bowel syndrome within a year of an intestinal infection, representing a risk that is four times higher than in those who don’t experience such an infection. This, coupled with a recently updated report from the International Foundation for Functional Gastrointestinal Disorders which states that there are up to 45 million IBS sufferers in the United States, further entrenches the disease's reputation as a costly and challenging affliction that often goes undiagnosed and untreated.

Biomerica's product (InFoods IBS), is a simple blood test that identifies the body's reactions to specific foods, as opposed to food groups, allowing medical staff to provide therapeutic guidance on which foods should be removed from a patient's diet to alleviate symptoms. This approach is intended to address all three forms of IBS and focuses on food, one possible underlying cause for symptoms. The FDA has recently determined that the proposed study design for the validation of the product is a non-significant risk device study, thus the Company will not be required to submit an investigational device exemption (IDE) for the InFoods IBS product clinical study. 

"IBS remains a largely untreatable burden for up to 45 million people in the United States who desperately seek some form of medical advancement providing symptom relief," says Zackary Irani, CEO of Biomerica, Inc. "We believe our approach, led by a Scientific Advisory Board and Strategic Advisory Board comprised of the leading minds in the IBS medical industry, is the key differentiator between our InFoods IBS diagnostic guided therapy and the treatment-based products currently available to patients. We continue to work with the FDA and leading research groups to further enhance the technology and its results, and hope to bring a more effective, non-drug solution to IBS patients everywhere."

About Biomerica (NASDAQ: BMRA)
Biomerica, Inc. (
www.biomerica.com) is a global biomedical company that develops, manufactures and markets advanced diagnostic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for the early detection of medical conditions and diseases. The Company's products are designed to enhance health and well-being, while reducing total healthcare costs. Biomerica primarily focuses on products for Gastrointestinal Disease, Diabetes and esoteric testing.
This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

Corporate Contact:
Zackary Irani
949-645-2111

Media Contact:
Kate Caruso-Sharpe
646-699-1414
kate@fischtankpr.com